A phase I study of flavopiridol and docetaxel

Investigational New Drugs

Volumn 24, Issue 4, 2006, Pages 305-310

  El Rayes, Basil F ^a   Gadgeel, Shirish ^a   Parchment, Ralph ^a   Lorusso, Patricia ^a   Philip, Philip A ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Docetaxel; Flavopiridol; Phase I

Indexed keywords

BISMUTH SALICYLATE; CYCLIN DEPENDENT KINASE INHIBITOR; DOCETAXEL; FLAVOPIRIDOL; TAXANE DERIVATIVE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CELL CYCLE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG MECHANISM; FEVER; HUMAN; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; FLAVONOIDS; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; PROTEIN KINASE INHIBITORS; TAXOIDS; TIME FACTORS;

EID: 33646497497     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-005-4343-5     Document Type: Article

References (25)

1. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100(1):57-70, 2000
2. Morgan DO: Cyclin-dependent kinases: Engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13:261-291, 1997
3. Shah MA, Schwartz GK: Cell cycle-mediated drug resistance: An emerging concept in cancer therapy. Clin Cancer Res 7(8):2168-2181, 2001
4. Senderowicz AM, Sausville EA: Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 92(5):376-387, 2000
5. Sedlacek HH: Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol 38(2):139-170, 2001
6. Carlson B, Lahusen T, Singh S, Loaiza-Perez A, Worland PJ, Pestell R, Albanese C, Sausville EA, Senderowicz: Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 59(18):4634-4641, 1999
7. Li Y, Bhuiyan M, Alhasan S, Senderowicz AM, Sarkar FH: Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol. Clin Cancer Res 6(1):223-229, 2000
8. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ: Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56(13):2973-2978, 1996
9. Motwani M, Rizzo C, Sirotnak F, She Y, Schwartz GK: Flavopiridol enhances the effects of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther 2(6):549-555, 2003
10. Motwani M, Delohery TM, Schwartz GK: Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 5(7):1876-1883, 1999
11. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Hill K, Steinberg SM, Figg WD, Tompkins A, Arbuck SG, Sausville EA: Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16(9):2986-2999, 1998
12. Thomas JP, Tutsch KD, Cleary JF, Bailey HH, Arzoomanian R, Alberti D, Simon K, Feierabend C, Binger K, Marnocha R, Dresen A, Wilding G : Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 50(6):465-472, 2002
13. Schwartz GK, O'Reilly E, Ilson D, Saltz L, Sharma S, Tong W, Maslak P, Stoltz M, Eden L, Perkins P, Endres S, Barazzoul J, Spriggs D, Kelsen D: Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 20(8):2157-2170, 2002
14. Huizing MT, Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CH, Vermorken JB, Pinedo HM, Beijnen JH: Taxanes: A new class of antitumor agents. Cancer Invest 13(4):381-404, 1995
15. Grant DS, Williams TL, Zahaczewsky M, Dicker AP: Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 104(1):121-129, 2003
16. Crown J: Docetaxel: Overview of an active drug for breast cancer. Oncologist 6(Suppl 3):1-4, 2001
17. Leahy M, Howell A: Docetaxel. Br J Hosp Med 57(4): 141-144, 1997
18. Lee SH, Yoo SD, Lee KH: Rapid and sensitive determination of paclitaxel in mouse plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 724(2):357-363, 1999
19. Schwartz GK, Ilson D, Saltz L, O'Reilly E, Tong W, Maslak P, Werner J, Perkins P, Stoltz M, Kelsen D: Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 19(7): 1985-1992, 2001
20. Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D, Vokes EE: Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago Phase II Consortium study. J Clin Oncol 18(2):371-375, 2000
21. Shapiro GI, Supko JG, Patterson A, A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 7(6):1590-1599, 2001
22. Clarke SJ, Rivory LP: Clinical pharmackokinetics of docetaxel. Clin Pharmacokinetics 36(2):99-114, 1999
23. Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M: Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53(5):1037-1042, 1993
24. Rosing H, Lustig V, van Warmerdam LJ, Huizing MT, ten Bokkel Huinink WW, Schellens JH, Rodenhuis S, Bult A, Beijnene JH: Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion. Cancer Chemother Pharmacol 45(3):213-218, 2000
25. Bruno R, Riva A, Hille D, Lebecq A, Thomas L: Pharmacokinetic and pharmacodynamic properties of docetaxel: Results of phase I and phase II trials. Am J Health Syst Pharm 54(24 Suppl 2):S16-S19, 1997